News

Dr. Dolly Jacob, Director of Integrated Development Services at Quotient Sciences featured in Drug Development & Delivery looking at the challenges of solubility & bioavailability.

An expansion of our early-phase formulation development capabilities for oral dosage forms at our Nottingham, UK, facility builds upon our existing formulation capabilities.

Andy Lewis, Vice President, Pharmaceutical Sciences, has written an article for Drug Development & Delivery entitled, "Alternative Strategies for Development of Modified-Release Dosage Forms"

John McDermott, Quotient Sciences' Executive Drug Development Consultant, discusses Integrated Development Strategies Overcome Solubility Challenges, in Drug Development & Delivery's Special Feature.

Oxilio signed an exclusive global licensing agreement with TRx Biosciences on 20th October 2021 for the use of their platformtechnology to support the development of Oxilio’s formulation, OXL001. Oxilio has since progressed the product and nowsigned a significant service contract with Quotient Sciences, a drug development and manufacturing accelerator, to support the formulation development and preparation of clinical trials for OXL001.